StereotaxisSTXS 66 FCF Margin % is -55.97% as of Mar. 2026. GuruFocus rates STXS with a GF Score™ of 66/100 and a GF Value™ of $2.31 (Modestly Undervalued). The stock has 4 warning signs investors should review. Among 815 Medical Devices & Instruments companies, Stereotaxis ranks worse than 78.65% on this metric.
FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Stereotaxis's Free Cash Flow for the
three
months ended in Mar. 2026 was $-3.52 Mil. Stereotaxis's Revenue for the
three
months ended in Mar. 2026 was $6.29 Mil. Therefore, Stereotaxis's FCF Margin % for the quarter that ended in Mar. 2026 was -55.97%.
The historical rank and industry rank for Stereotaxis's FCF Margin % or its related term are showing as below:
STXS'
s FCF Margin % Range Over the Past 10 Years
Min: -49.45 Med: -18.88 Max: -9.58
Current: -49.45
During the past 13 years, the highest FCF Margin % of Stereotaxis was -9.58%. The lowest was -49.45%. And the median was -18.88%.
STXS's FCF Margin % is ranked worse than 78.65% of 815
companies
in the Medical Devices & Instruments industry
Industry Median: -0.1
vs STXS: -49.45
Stereotaxis FCF Margin % Related Terms
Stereotaxis FCF Margin % Historical Data
* Premium members only.
The historical data trend for Stereotaxis's FCF Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Instruments & Supplies subindustry, Stereotaxis's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Stereotaxis FCF Margin % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Stereotaxis's FCF Margin % distribution charts can be found below:
* The bar in red indicates where Stereotaxis's FCF Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Stereotaxis (STXS) has a FCF Margin % of -55.97% as of Mar. 2026. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Stereotaxis and its competitors. According to the industry distribution chart, Stereotaxis ranks #641 out of 815 companies in the Medical Devices & Instruments industry, placing it in the top 78.7%.
Is Stereotaxis' FCF Margin % too high?
Stereotaxis' current FCF Margin % is -55.97%. Based on the distribution chart, Stereotaxis ranks #641 out of 815 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Stereotaxis has a GF Score™ of 66/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Stereotaxis' FCF Margin % compare to EMBC and KRMD?
According to the Medical Devices & Instruments industry distribution chart, Stereotaxis ranks #641 out of 815 companies for FCF Margin %. This places Stereotaxis in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Margin % for a Medical Devices & Instruments company?
A good FCF Margin % depends on the Medical Devices & Instruments industry context. However, FCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Margin % mean?
A high FCF Margin % can signal that a stock is expensive relative to its fundamentals. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Stereotaxis and its competitors. Stereotaxis's current FCF Margin % is -55.97%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Stereotaxis stock overvalued right now?
Based on GuruFocus' analysis, Stereotaxis (STXS) is currently considered Modestly Undervalued. The stock's GF Value™ is $2.31, compared to a current price of $1.63 — trading 29.4% below its estimated fair value. The current FCF Margin % is -55.97%. Stereotaxis' overall GF Score™ is 66/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Margin % calculated?
FCF Margin % is calculated from a company's financial statements. For Stereotaxis (STXS), the current FCF Margin % is -55.97% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Stereotaxis (STXS) Overvalued in 2026?
Based on GuruFocus' analysis, Stereotaxis stock appears to be undervalued.
The current stock price of $1.63 is trading 29.4% below its estimated GF Value™ of $2.31.
GuruFocus considers Stereotaxis to be Modestly Undervalued.
Key valuation signals for STXS:
FCF Margin %: -55.97%
GF Value™: $2.31 vs. price of $1.63 (29.4% below fair value)
No single metric tells the full story. See the STXS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Stereotaxis Inc is engaged in robotic technologies designed to enhance the treatment of arrhythmias and perform endovascular procedures. The company's mission is the discovery, development, and delivery of robotic systems, instruments, and information solutions for the interventional laboratory. These innovations help physicians provide patient care with robotic precision and safety, improved lab efficiency and productivity, and enhanced integration of procedural information. The company's revenue generation is derived from the streams of Systems, Disposables, Royalty, and Sublease, of which a majority of revenue is generated from the Disposables, service, and accessories stream.
66GF Score
Get the complete analysis for STXS
FCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STXS has been successfully added to your 
